悦康药业：2025年年度业绩预亏2.35亿-2.80亿元

Core Viewpoint - The company expects a significant net loss for the fiscal year 2025, with projected losses ranging from 280 million to 235 million yuan, compared to a profit of 124 million yuan in the same period last year [1] Financial Performance - The anticipated net profit attributable to the parent company is projected to be between -280 million and -235 million yuan for 2025, a stark contrast to the previous year's profit of 124 million yuan [1] - The expected non-recurring net profit is forecasted to be between -305 million and -260 million yuan, down from 111 million yuan in the prior year [1] Factors Influencing Performance - The primary reason for the expected losses is attributed to adjustments in pricing and sales strategies for the "Ginkgo Biloba Extract Injection" at the end of 2024, which is anticipated to have a significant impact on revenue and profit [1] - Additionally, the company has experienced an increase in research and development expenses compared to the previous year [1]